LO-BLISOVI FE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LO-BLISOVI FE (LO-BLISOVI FE).
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
| Metabolism | Hepatic via CYP3A4 (ethinyl estradiol) and primarily conjugation (norethindrone); first-pass metabolism. |
| Excretion | Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%) |
| Half-life | Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing |
| Protein binding | Ethinyl estradiol: 95-98% bound to albumin and sex hormone-binding globulin (SHBG) |
| Volume of Distribution | Ethinyl estradiol: 2-5 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: ethinyl estradiol approximately 40-50% (first-pass metabolism) |
| Onset of Action | Oral: contraceptive effect established within 7 days of continuous dosing |
| Duration of Action | Duration: 24 hours; requires daily dosing for maintained suppression of ovulation |
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required in renal impairment. Use with caution if severe renal impairment or nephrotic syndrome due to potential fluid retention. |
| Liver impairment | Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Not recommended in moderate impairment (Child-Pugh B) without specialist advice. No data for mild (Child-Pugh A); use caution. |
| Pediatric use | Not indicated in pediatric patients before menarche. For postmenarchal females, same adult dose may be used; weight-based dosing not established. |
| Geriatric use | Not indicated in postmenopausal women. No specific geriatric dose adjustments; consider increased risk of thrombotic events and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LO-BLISOVI FE (LO-BLISOVI FE).
| Breastfeeding | Small amounts of progestins and estrogens are excreted in breast milk; M/P ratio not established for this specific formulation. Use in breastfeeding women is generally not recommended due to potential effects on milk production and composition, and possible long-term effects on the infant. Alternative contraception methods are advised until weaning. |
| Teratogenic Risk | Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-trimester exposure, and potential feminization of male fetuses from progestin exposure. Post-conception use is not indicated; if exposure occurs, evaluate for pregnancy. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from COC use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use COCs.
| Serious Effects |
["Venous or arterial thrombotic/thromboembolic events (current or history)","Cerebrovascular or coronary artery disease","Valvular heart disease with complications","Uncontrolled hypertension","Major surgery with prolonged immobilization","Diabetes with vascular involvement","Headache with focal neurological symptoms or migraine with aura (age ≥35)","Current or history of breast cancer or other estrogen-sensitive neoplasia","Hepatic adenomas or malignant liver tumors","Acute or chronic liver disease with abnormal function","Undiagnosed abnormal uterine bleeding","Known or suspected pregnancy","Cigarette smoking in women >35 years","Hypersensitivity to any component"]
| Precautions | ["Thrombotic disorders (DVT, PE, stroke, MI)","Carcinoma (breast, cervical, liver)","Hepatic disease (jaundice, cholestasis)","Hypertension","Carbohydrate/lipid effects","Headache/migraine","Bleeding irregularities","Drug interactions (CYP3A4 inducers/inhibitors)","Depression","Gallbladder disease","Hereditary angioedema"] |
Loading safety data…
| Fetal Monitoring | Monitor for pregnancy before initiation and during use if pregnancy suspected. If inadvertent use during pregnancy, perform fetal ultrasound to assess for anomalies. No specific fetal monitoring required beyond standard prenatal care if exposure occurs. |
| Fertility Effects | Suppresses ovulation, thickens cervical mucus, and alters endometrial lining, resulting in contraceptive effect. Upon discontinuation, fertility returns, but there may be a short-term delay in resumption of ovulation, especially with prolonged use. No permanent negative effects on fertility. |